Blood pressure (BP) reduction is the key to risk reduction of cardiovascular disease or renal failure in hypertensive patients with diabetes mellitus. Inhibition of the renin-angiotensin system by an angiotensin-converting enzyme (ACE) inhibitor or an angiotensin II receptor blocker (ARB) provides efficient BP reduction and renal protection in hypertensive diabetes patients. But, despite this, the recommended BP levels can be difficult to achieve and dual blockade therapy might be a possible way of obtaining efficient BP reduction in hypertensive patients with diabetes.
Abstract
Background Blood pressure (BP) reduction is the key to risk reduction of cardiovascular disease or renal failure in hypertensive patients with diabetes mellitus. Inhibition of the renin-angiotensin system by an angiotensin-converting enzyme (ACE) inhibitor or an angiotensin II receptor blocker (ARB) provides efficient BP reduction and renal protection in hypertensive diabetes patients. But, despite this, the recommended BP levels can be difficult to achieve and dual blockade therapy might be a possible way of obtaining efficient BP reduction in hypertensive patients with diabetes.
Dual blockade treatment is based on a principle of obtaining the broadest and most efficient blockade of angiotensin II, by using the combination of an ACE-inhibitor and an ARB.
Methods
The Candesartan And Lisinopril Microalbuminuria (CALM II) study is a one centre, one observer, double-blind, randomised, active-controlled, parallel-group study, investigating the efficacy and tolerability of candesartan cilexetil in combination with lisinopril, compared with the maximum recommended dose of lisinopril in hypertensive patients with diabetes mellitus.
The study design consists of two treatment arms with either 16 mg candesartan cilexetil or 20 mg lisinopril added to concomitant treatment with 20 mg lisinopril. It comprises 80 patients with a minimum of 35 patients in each group and statistical power of 90% to detect a difference in systolic BP reduction of 6.5 mmHg.
Introduction
The role of angiotensin-converting enzyme (ACE)escape and unopposed stimulation of subclasses of angiotensin II (Ang II) AT-receptors has a major bearing on the question of whether combined therapy with Ang II receptor blockers (ARBs), which block the AT 1 -receptor, and an ACE inhibitor that blocks the conversion of angiotensin I to Ang II, will exert additive benefit. 1 Dual blockade treatment is based on a principle of obtaining the most extensive and efficient blockade of the effects of Ang II, and maybe also an intensification of the beneficial effects of bradykinin on blood pressure (BP) and renal function, because of reduced degradation of this metabolite.
Only a few studies have been published using dual blockade treatment in patients with diabetes mellitus. These studies have primarily included diabetic patients with nephropathy and have, in all cases, demonstrated significant reduction in systolic and diastolic BP and albuminuria, but only with a short follow-up. [2] [3] [4] [5] Since the recommended BP levels can be difficult to achieve, despite multiple drug therapy, dual blockade therapy might be the way to obtain efficient BP reduction in hypertensive patients with diabetes.
The Candesartan And Lisinopril Microalbuminuria (CALM II) study is a new study based on the findings in the CALM study and seeks to investigate effects of dual blockade on systolic BP (SBP), albuminuria, left ventricular (LV) mass and function, and finally retinopathy, in hypertensive patients with diabetes mellitus over a 12-month follow-up period.
Study objectives
The primary objective of the study is to compare the reduction of SBP by adding either candesartan cilexetil, 16 mg, or lisinopril, 20 mg, to concomitant antihypertensive treatment with lisinopril, 20 mg, in subjects with diabetes mellitus.
Secondary objectives are to estimate the effects of high-dose lisinopril or the combination of candesartan and lisinopril, on LV mass and diastolic function, urinary-albumin: creatinine ratio (UACR), and retinopathy.
The study will also assess the safety and tolerability of the two treatment arms.
Inclusion criteria
For inclusion in the study, subjects must fulfil all of the following criteria: 1. Sitting office SBP 120-160 mmHg (mean of three measurements) on treatment with lisinopril 
Blood pressure assessment
The primary endpoint is reduction in 24-hour SBP. Diastolic BP (DBP) reduction is a secondary endpoint.
Seated BP will be assessed throughout the study period. Measurements of seated BP will be performed by sphygmomanometry with an appropriately-sized cuff, at trough drug levels, after 15 minutes of rest. If the SBP is above 160 mmHg or the DBP above 90 mmHg, 2.5 mg bendroflumethiazide will be added. If the BP is not below the target level with supplemental thiazide diuretic treatment, the patient will be excluded.
If the SBP is below 110 mmHg, the patient will also be excluded. There is no lower level of DBP reduction.
24-hour BP recordings at baseline and after 12 months, are measured by an oscillometric technique (SpaceLabs 91207), 6 with readings at 20minute intervals throughout 24 hours. Measurements are performed during a day with normal activities at home or at work. Individually reported sleeping times are implemented in the calculation of day and night BP.
Echocardiography
The objective is to assess any reduction in LV mass and improvement in LV diastolic function. To investigate this, all patients undergo echocardiographic examination by the same observer at baseline and at three and 12 months follow-up. All echocardiography examinations are performed on a GE Vivid Five ultrasound machine (GE Medical System, Horden, Norway) with a 2.5 MHz transducer. The echocardiographic protocol specifies five cycles of parasternal long axis views to obtain optimal M-Mode recordings of LV diameters and wall diameters. LV volumes and ejection fraction are estimated using Simpson's modified biplane method, based on three measurements. 7 Pulsed Doppler measurements will be obtained with the transducer in the apical four-chamber view, with the Doppler beam aligned perpendicular to the plane of the mitral annulus.The sample volume is placed between the tips of the mitral leaflets. 8 Five consecutive beats during quiet respiration are used for calculation of the Doppler variables.
Colour M-Mode flow propagation recordings are assessed from the apical four-chamber view,with the M-Mode cursor aligned parallel with the LV inflow. 9
Urinary albumin excretion
Since urinary albumin excretion shows a considerable intra-individual variability with a day-to-day variation of 30-50%, 10 we evaluate UACR on the basis of three urine samples at baseline and at the 12-month follow-up visit, but only one sample at the intermediate visits. UACR will be estimated as the geometric mean of three UACR's from overnight urine samples collected within a week. 11 Urinary albumin concentration is determined by an immunoturbidimetric method (Roche Diagnostics, Basel, Switzerland). Patients will be classified as normo-albuminuric, (at least two out of three UACRs < 2.5 mg/mmol [ 
Assessment of retinopathy
Assessment of retinopathy will be performed at baseline and after 12 months' treatment.
A standard photograph of 60º of each eye will be taken centred on the foveal region, thus covering an area approximately corresponding to fields 1-5 of the standard fields used in the Early Treatment For Diabetic Retinopathy Study (ETDRS). 13 For the grading, each photograph is digitalised and evaluated independently by two experienced graders.The number of each pathological lesion, haemorrhages and/or microaneurysms, hard exudates, or cotton wool spots is counted and the presence of diabetic maculopathy is also noted. Each eye will be assigned an overall retinopathy grade on a scale from 1-6 according to the principles used in the Wisconsin Epidemiologic Study of Diabetic Retinopathy, 14 with a modification to ensure that lesions implying the same risk of progression to proliferative diabetic retinopathy resulted in the same retinopathy level (ETDRS Report 12). 15
Tolerability and safety
Dual blockade is generally well tolerated and only reversible side-effects have yet been reported. Typical side-effects are cough, feeling weak, hypotension and hyperkalaemia.
In previously published reviews of dual blockade trials, incidences of side-effects were between 0.6-10.9%. 16 The incidence of all adverse events, serious adverse events and adverse events leading to discontinuation, for all patients who received at least one dose, will be assessed.
Additionally, there will be close monitoring of renal function by assessment of serum-potassium and serum-creatinine throughout the study period.
A schematic display of the course of the study is provided in Table 1 , and Figure 1 . 
Statistical considerations and sample size
From previous studies, the standard deviation of the change in SBP measured at trough (24 hours) was estimated to be 7 mmHg. 17 A standard deviation of that magnitude would require a sample size of 70 subjects, 35 in each treatment arm, for a power of 90% to detect a difference of 6.5 mmHg to be tested at a two-sided significance level of 5%. The aim is to include 80 patients to replace dropouts and excluded patients.
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Conclusion
The CALM II study is the first study to examine the effects of dual blockade on LV function and retinopathy in patients with diabetes, and will also provide the longest follow-up of the effects on BP and albuminuria in a diabetic population.
Results are due in the autumn of 2004. 
